Heartburn and arthritis drugs tested against COVID-19
NCT ID NCT05077332
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This Phase 2 trial tested whether combining famotidine (Pepcid) and celecoxib (Celebrex) could help people with COVID-19 recover faster. Only 4 participants were enrolled, making it too small to draw firm conclusions. The study aimed to see if these drugs could reduce symptom severity and prevent hospital visits.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Famotidine (Pepcid) and celecoxib (Celebrex)
- What this could lead to
- If it works, this could point toward a safe, over-the-counter drug combination to help manage COVID-19 symptoms at home.
- What could go wrong
- This was a very small, early-phase trial with only 4 participants, so results are not reliable. The drugs may not work against COVID-19, and side effects are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for 2019 NOVEL CORONAVIRUS DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
US02-04: Integrated Health Solutions
Miami, Florida, 33126, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Five years on: how does long COVID evolve?
- Can a targeted pill tame severe COVID-19?
- Can an organic compound tame COVID-19 in High-Risk patients?
- Could exercise retrain the heart in long COVID?
- Can a new drug shield lungs from COVID-19's worst damage?
- Can paxlovid hold the line against severe COVID-19 outside the lab?